DOvEEgene/WISE Genomics: Diagnosing Ovarian and Endometrial Cancer Early Using Genomics
Recruiting now NCT02288676
Run by McGill University · for 18 and older · Women
What this study is about
This study aims to develop and validate a test for detecting ovarian and endometrial cancers early. It relies on detecting somatic mutations that are associated with these cancers from a uterine pap test. A saliva sample is also collected that acts as an internal control and has the ability to detect deleterious germline mutations associated with common hereditary cancers (such as breast, ovarian, endometrial, colon, and pancreatic cancers). A machine learning classifier is then used to discriminate between cancer and benign disease.
Who can join (things the study team will check)
Case Inclusion: * Subjects should have suspected or confirmed cancer of the upper genital tract. * Participant will undergo surgery for tumour removal. Control inclusion: • Subjects should be scheduled to have a hysterectomy, bilateral salpingectomy, with or without bilateral oophorectomy, for presumed benign disease.…
Where this trial is running
- Royal Victoria Hospital (Glen Site), Montreal, Quebec, Canada
Who to contact
Dr. Lucy Gilbert, MD,MSc,FRCOG · (514) 934-1934 · lucy.gilbert@mcgill.ca
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT02288676.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.